INmune Bio Inc（INMB）财务数据INMBINmune Bio Inc

Evaluating the bottom line, INmune Bio Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -74.82%, provide a clear picture of how effectively INMB converts its operational activities into shareholder value.

In the context of the broader market, INMB competes directly with industry leaders such as ZYBT and BCTX. With a market capitalization of $34.68M, it holds a significant position in the sector. When comparing efficiency, INMB's gross margin of N/A stands against ZYBT's 20.51% and BCTX's N/A. Such benchmarking helps identify whether INmune Bio Inc is trading at a premium or discount relative to its financial performance.

The company has reported no revenue in several quarters and significant net losses, including a $24.46 million loss in Q2 2025, which raises concerns about its financial viability.